Cited by 373Gastrointestinal motility and disordersPelvic floor disorders treatmentsCongenital gastrointestinal and neural anomalies

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Two Randomized Trials of Linaclotide for Chronic Constipation

Open access

Lembo, Anthony J., Schneier, Harvey A., Shiff, Steven J., Kurtz, Caroline B., MacDougall, James E., Jia, Xinwei D., Shao, James Z., Lavins, Bernard J., Currie, Mark G., Fitch, Donald A., Jeglinski, Brenda I., Eng, Paul, Fox, Susan M., Johnston, Jeffrey M.·2011·New England Journal of Medicine

DOI 10.1056/nejmoa1010863

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Linaclotide is a minimally absorbed peptide agonist of the guanylate cyclase C receptor. In two trials, we aimed to determine the efficacy and safety of linaclotide in patients with chronic constipation. METHODS: We conducted two randomized, 12-week, multicenter, double-blind, parallel-group, placebo-controlled, dual-dose trials (Trials 303 and 01) involving 1276 patients with chronic constipation. Patients received either placebo or linaclotide, 145 μg or 290 μg, once daily for 12 weeks. The primary efficacy end point was three or more complete spontaneous bowel movements (CSBMs) per week and an increase of one or more CSBMs from baseline during at least 9 of the 12 weeks. Adverse events were also monitored. RESULTS: For Trials 303 and 01, respectively, the primary end point was reached by 21.2% and 16.0% of the patients who received 145 μg of linaclotide and by 19.4% and 21.3% of the patients who received 290 μg of linaclotide, as compared with 3.3% and 6.0% of those who received placebo (P<0.01 for all comparisons of linaclotide with placebo). Improvements in all secondary end points were significantly greater in both linaclotide groups than in the placebo groups. The incidence of adverse events was similar among all study groups, with the exception of diarrhea, which led to discontinuation of treatment in 4.2% of patients in both linaclotide groups. CONCLUSIONS: In these two 12-week trials, linaclotide significantly reduced bowel and abdominal symptoms in patients with chronic constipation. Additional studies are needed to evaluate the potential long-term risks and benefits of linaclotide in chronic constipation. (Funded by Ironwood Pharmaceuticals and Forest Research Institute; ClinicalTrials.gov numbers, NCT00765882 and NCT00730015.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1010863

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Stool form scale as a useful guide to intestinal transit time
Lewis, S. J., & Heaton, K. W. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709011203 · Cited by 3,244
Epidemiology of Constipation in North America: A Systematic Review
Higgins, P., & Johanson, J. (2004) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.04114.x · Cited by 1,048
Chronic Constipation
Lembo, A., & Camilleri, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020995 · Cited by 692
Self-citation
Chronic constipation: a survey of the patient perspective
JOHANSON, J. F., & KRALSTEIN, J. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03238.x · Cited by 617
Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire
Marquis, P., de la Loge, C., Dubois, D., Mcdermott, A., & Chassany, O. (2005) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520510012208 · Cited by 586
Heat-stable enterotoxin of Escherichia coli: in vitro effects on guanylate cyclase activity, cyclic GMP concentration, and ion transport in small intestine.
Field, M., Graf, L. H., Laird, W., & Smith, P. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.6.2800 · Cited by 561
AGA Medical Position Statement on the Diagnosis and Management of Colorectal Neoplasia in Inflammatory Bowel Disease
Farraye, F. A., Odze, R. D., Eaden, J., & Itzkowitz, S. H. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.037 · Cited by 530
An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking
Paré, P., Ferrazzi, S., Thompson, W., Irvine, E. J., & Rance, L. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.05259.x · Cited by 445
The burden of constipation on quality of life: results of a multinational survey
Wald, A. M., Scarpignato, C., Kamm, M. A., Mueller‐Lissner, S., HELFRICH, I., Schuijt, C., Bubeck, J., Limoni, C., & Petrini, O. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03376.x · Cited by 374
Systematic Review on the Management of Chronic Constipation in North America
Brandt, L. J., Prather, C. M., Quigley, E. M. M., Schiller, L. R., Schoenfeld, P., & Talley, N. J. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.50613_2.x · Cited by 344

Show all 18 references

Research works printed but not linked: 1

Martin BC, 2006, Manag Care Interface, 19, 43

Sorted by citations

Items 201–300 of 372

Interferential therapy for chronic constipation in adults: The CON‐COUR randomizedcontrolled trial
Vitton, V., Mion, F., Leroi, A., Brochard, C., Coffin, B., Zerbib, F., Damon, H., Melchior, C., Duboc, H., Queralto, M., et al. (2023) · United European Gastroenterology Journal · doi:10.1002/ueg2.12373 · Cited by 10
Chronic constipation
Lembo, A. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13911-6.00009-8 · Cited by 10
Self-citation
Understanding constipation as a geriatric syndrome
Cheever, C. R., Shams, R. B., Willingham, K. R., Sim, H., Cook, L. M., Ahmidouch, M. Y., Scholand, K. E., & Wilson, L. A. (2024) · Geriatric Nursing · doi:10.1016/j.gerinurse.2024.12.012 · Cited by 10
New treatment options for irritable bowel syndrome with predominant diarrhea
Weber, H. C. (2016) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000302 · Cited by 9
Linaclotide, Novel Therapy for the Treatment of Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome
Vázquez‐Roque, M. I., & Bouras, E. P. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0012-9 · Cited by 10
“Two randomized, multicenter, double-blind, placebo-controlled, dual-dose trials, denoted 303 and 01, in 1,276 patients with CC were conducted [32].”
Method
Linaclotide: A New Option for the Treatment of Irritable Bowel syndrome with Constipation and Chronic Idiopathic Constipation in Adults
Parker, C. H., Yuan, Y., & Liu, L. W. C. (2013) · Clinical Medicine Insights Gastroenterology · doi:10.4137/cgast.s10550 · Cited by 11
Emerging treatments for chronic constipation
Gudsoorkar, V. S., & Quigley, E. M. M. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2013.831068 · Cited by 10
“Reflecting its negligible systemic absorption, the main adverse event experienced in these studies has been diarrhea; notably, nausea has not been an issue [53-56].”
Background
New treatment targets for the management of irritable bowel syndrome
Rao, S., & Weber, H. (2014) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000034 · Cited by 10
“bowel and abdominal symptoms in patients with CIC [68].”
Background
Comparison of acupuncture and other drugs for chronic constipation: A network meta-analysis
Zhu, L., Ma, Y., & Deng, X. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196128 · Cited by 11
Retracted
Fundamental Neurochemistry Review: The role of enteroendocrine cells in visceral pain
Londregan, A., Alexander, T. D., Covarrubias, M., & Waldman, S. A. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.16022 · Cited by 12
“Beyond constipation, in clinical trials lin-aclotide also significantly relieved abdominal pain, compared to placebo (Chey et al., 2012; Lembo et al., 2011; Rao et al., 2012).”
Background
Phosphorylation-Dependent Regulation of Guanylyl Cyclase (GC)-A and Other Membrane GC Receptors
Potter, L. R. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae015 · Cited by 11
Randomized controlled trial of linaclotide in children aged 6−17 years with functional constipation
Lorenzo, C. D., Nurko, S., Hyams, J. S., Rodriguez‐Araujo, G., Almansa, C., Shakhnovich, V., Saps, M., & Simon, M. W. (2024) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.12184 · Cited by 10
Update on the Management of Chronic Constipation
Koliani‐Pace, J. L., & Lacy, B. E. (2017) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-017-0118-2 · Cited by 9
Targeted pharmacotherapy of irritable bowel syndrome.
Arokiadoss, A., & Weber, H. (2021) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000618 · Cited by 9
The effect of electroacupuncture at ST25 on Parkinson's disease constipation through regulation of autophagy in the enteric nervous system
Song, L.-Z.-X., Xu, N., Yu, Z. H., Yang, H., Xu, C., Qiu, Z., Dai, J., Xu, B., & Hu, X. (2023) · The Anatomical Record · doi:10.1002/ar.25148 · Cited by 9
“…addressed with symptomatic treatment strategies, and medications commonly used on the clinical front have significant side effects and limitations (Eichhorn & Oertel, 2001; Jost, 2010; Lembo, Johanson, et al., 2011; Lembo, Schneier, et al., 2011; Ondo et al., 2012; Sullivan et al., 2006) (Table 1).”
Background
Current Treatment Practices for Adult Patients with Constipation in Japan
Kessoku, T., Misawa, N., Ohkubo, H., & Nakajima, A. (2023) · Digestion · doi:10.1159/000533548 · Cited by 9
“Therefore, linaclotide can treat constipation-type irritable bowel syndrome [34].”
Background
Recent Updates on the Treatment of Constipation
Ryu, H. S., & Choi, S. C. (2015) · Intestinal Research · doi:10.5217/ir.2015.13.4.297 · Cited by 9
“36.0% improvement after 26 weeks of administration.40 Linaclotide affects the colonic sensory afferents in patients with chronic visceral hypersensitivity by reducing the activity of pain-sensing fibers by elevating extracellular cyclic guanosine-3’,5’-monophosphate (cGMP) levels.41 The superior effect of linaclotide…”
BackgroundInfluential
Expert Consensus Document: An Algorithm for the Care and Treatment of Patients with Constipation Based on Ultrasonographic Findings in the Rectum
Kessoku, T., Matsumoto, M., Misawa, N., Tsuda, M., Miura, Y., Uchida, A., Toriumi, Y., Onodera, T., Arima, H., Kawamoto, A., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14141510 · Cited by 8
“It has been shown to be effective in treating constipation-type irritable bowel syndrome [40].”
Background
Recent advances in treating constipation in children
Wolfson, S. M., & Saps, M. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2383636 · Cited by 12
“In adults, linaclotide has been proven safe and effective for the treatment of FC and IBS-C [30,31].”
Motility disorders of the colon and rectum
Wald, A. (2012) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32834d4f61 · Cited by 3
“This article and its companion study [12] provide the data to support this novel intestinal secretagogue as an effective agent in both chronic constipation and IBS-C.”
Background
Does obesity promote the development of colorectal cancer?
Blomain, E. S., & Waldman, S. A. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1162102 · Cited by 8
Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers
Weinberg, D. S., Foster, N. R., Della’Zanna, G., McMurray, R. P., Kraft, W. K., Pallotto, A., Kastenberg, D. M., Katz, L. C., Henry, C. H., Moleski, S., et al. (2021) · Cancer Biology & Therapy · doi:10.1080/15384047.2021.1967036 · Cited by 8
“Generally, linaclotide is well tolerated, with side effects primarily reflecting on-target activity of GUCY2C mediation of fluid and electrolyte secretion, resulting in diarrhea.(28,29) The robust safety of this agent is underscored by the negligible bioavailability of orally administered linaclotide.”
BackgroundInfluential
Development of colonic transit time and ultrasound imaging tools as objective indicators for assessing abnormal defecation associated with food intake: a narrative review based on previous scientific knowledge
Okawa, Y. (2021) · BioPsychoSocial Medicine · doi:10.1186/s13030-021-00222-1 · Cited by 8
“It is possible to evaluate gastrointestinal function by evaluating the quantity and location of residual markers in the gastrointestinal tract on abdominal radiography [15, 16].”
Background
DIAGNOSIS AND MANAGEMENT OF CHRONIC IDIOPATHIC CONSTIPATION: A NARRATIVE REVIEW FROM A BRAZILIAN EXPERT TASK FORCE
Passos, M. D. C. F., Alvariz, R. C., ANDRÉ, E. A., Barbuti, R. C., Fillmann, H. S., MURAD-REGADAS, S. M., Filho, J. R., Perrotti, M., & GUEDES, L. S. (2022) · Arquivos de Gastroenterologia · doi:10.1590/s0004-2803.202200001-23 · Cited by 10
Evaluation and Treatment of Colonic Symptoms
Pasanen, M. E. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.01.009 · Cited by 8
“Diarrhea led to discontinuation in approximately 4% of subjects.(37) In addition, linaclotide has shown promise in subjects with IBS with constipation, with improvements in both spontaneous bowel movements and abdominal pain.”
Background
Drug pipeline is flush with new options for chronic constipation
Dolgin, E. (2012) · Nature Medicine · doi:10.1038/nm0912-1308 · Cited by 8
Non-pharmacological and drug treatment of autonomic dysfunction in multiple system atrophy: current status and future directions
Chen, B., Yang, W., Luo, Y., Tan, E., & Wang, Q. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11876-y · Cited by 7
“The specific usage is to take 290 or 145 μg linacetide 30 min before breakfast each day [157].”
Background
Effects of Transcutaneous Auricular Vagal Nerve Stimulation on Chronic Constipation: A Multicenter, Randomized Controlled Study
Liu, T., Wang, Z., Li, Y., Kang, X., Wang, X., Ren, G., Lv, Y., Li, J., Liu, Y., Liang, S., et al. (2025) · United European Gastroenterology Journal · doi:10.1002/ueg2.70041 · Cited by 7
“…in treatment satisfaction [27–29] (five‐point scale: 1 = not at all satisfied and 5 = extremely satisfied) and will-ingness to continue treatment [27] (five‐point scale: 1 = not at all satisfied and 5 = extremely satisfied) at week 4; and (5) Any adverse events that occurred during the study…”
Effects of linaclotide in the treatment of chronic constipation and irritable bowel syndrome with constipation: a meta-analysis
Zhao, Q., Fang, Y., Yan, C., Gao, J., Liu, Z., Zhu, H., Tang, D., & Wang, D. (2021) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1491-1784 · Cited by 7
“…Generation of random sequences Randomization hiding Blinding method Withdrawal and exit Score Lacy 2015 appropriate appropriate appropriate yes 7 Lembo 2011 appropriate appropriate appropriate yes 7 Schoenfeld 2018 unclear unclear appropriate yes 5 Fukudo 2019 appropriate appropriate…”
BackgroundMethod
Comparative Efficacy of Drugs for the Treatment of Chronic Constipation
Zhang, Y., Yin, F., Xu, L., Li, Y.-F., Chen, J., Liu, H., Zheng, Q., & Li, L. (2020) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001303 · Cited by 7
Linaclotide: new mechanisms and new promise for treatment in constipation and irritable bowel syndrome
Sood, R., & Ford, A. (2013) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622313500110 · Cited by 8
Peptide therapeutics for the treatment of gastrointestinal disorders
Fretzen, A. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.11.007 · Cited by 7
A Practical Approach to the Diagnosis and Treatment of Abdominal Bloating and Distension.
Cangemi, D. J., & Lacy, B. E. (2022) · PubMed Central · Cited by 7
Polyethylene glycol 3350 in the treatment of chronic idiopathic constipation: Post hoc analysis using FDA endpoints
Menees, S. B., Lembo, A. J., & Chey, W. D. (2022) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2022/3533504 · Cited by 6
Self-citation
Cystic fibrosis risk variants confer protection against inflammatory bowel disease
Yu, M., Zhang, Q., Yuan, K., Sazonovs, A., Stevens, C. R., Fachal, L., Lamb, C. A., Anderson, C. A., Daly, M. J., & Huang, H. (2025) · Cell Genomics · doi:10.1016/j.xgen.2025.101071 · Cited by 9
“170 of the 1,036 CFTR variants were annotated in CFTR2 as ‘‘CF-causing’’ (109), ‘‘Varying clinical consequence’’ (33), ‘‘Non CF-causing’’ (19), or ‘‘Unknown signif-icance’’ (9).”
Bowel preparation with linaclotide and 1 L polyethylene glycol plus ascorbic acid prior to colonoscopy in chronic constipated patients
Maeda, N., Higashimori, A., Yamamoto, I., Kin, D., Morimoto, K., Nakatani, M., Sasaki, E., Fukuda, T., Arakawa, T., & Fujiwara, Y. (2024) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2024.2398094 · Cited by 6
“Linaclotide can increase luminal fluid secretion and mediate visceral analgesia, thereby inducing a laxative effect and improving abdominal symptoms [28–32].”
A novel treatment for patients with constipation: Dawn of a new age for translational microbiome research?
Shah, A., Morrison, M., & Holtmann, G. (2018) · Indian Journal of Gastroenterology · doi:10.1007/s12664-018-0912-3 · Cited by 6
Clinical response to linaclotide at week 4 predicts sustained response in irritable bowel syndrome with constipation and improvements in digestive and extra-digestive symptoms
Falcón, B. S., Delgado-Aros, S., Mearin, F., Ríos, C. C. D. L., Serra, J., Mínguez, M., Montoro, M. A., Juan, A. P., Santander, C., Aísa, Á. P., et al. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819857358 · Cited by 6
Real-World Comparison of Elobixibat and Lubiprostone Treatment in Patients with Chronic Constipation: A Propensity Score-Matched Analysis
Eguchi, T., Yoshizaki, T., Ikeoka, S., Takagi, M., Fujinami, M., Matsuda, T., Yamaguchi, T., Nonaka, T., Amioka, S., Katayama, N., et al. (2020) · Digestive Diseases · doi:10.1159/000512745 · Cited by 6
Approach to the Patient with Constipation
Rao, S. S. C., & Camilleri, M. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch42 · Cited by 6
Symptoms of Constipation: Relationship Between Questionnaires and Diaries and Impact on Quality of Life
Snih, G. M. A., Bailey, K. R., Oblizajek, N. R., & Bharucha, A. E. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.05.005 · Cited by 5
Linaclotide: evidence for its potential use in irritable bowel syndrome and chronic constipation
Wald, A. M., & Lee, N. (2012) · Core evidence · doi:10.2147/ce.s25240 · Cited by 5
“In trial 303, which included an additional 4 weeks, patients who continued to take linaclotide and those who were switched from placebo to linaclotide had sustained increases in the frequency of CSBMs similar to levels reported during the treatment period, whereas patients who switched from linaclotide to placebo had…”
BackgroundResultInfluential
Clarification of Linaclotide Pharmacology Presented in a Recent Clinical Study of Plecanatide
Busby, R. W., & Ortiz, S. R. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2953-x · Cited by 5
“’’ The high incidence of diarrhea observed in clinical evaluations with linaclotide [9] may possibly be due to uncontrolled activation of GC-C receptors in the GI tract due to the lack of luminal pHdependence of linaclotide in activation of GC-C receptors, compared with the pH-dependence of GC-C activation by its phys…”
Background
Habit training versus habit training with direct visual biofeedback in adults with chronic constipation: A randomized controlled trial
Norton, C. S., Bannister, S., Booth, L. R., Brown, S. R., Cross, S., Eldridge, S. M., Emmett, C., Grossi, U., Jordan, M., Lacy‐Colson, J., et al. (2023) · Colorectal Disease · doi:10.1111/codi.16738 · Cited by 5
“Chronic constipation was defined according to pragmatic criteria: broadly those employed for recent pivotal trials of prokinetics [21, 22] and UK guidance [ 23 ].”
Method
Motility disorders of the colon and rectum
Gras-Miralles, B., Magge, S., Bloom, A., & Lembo, A. J. (2012) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32835a80e7 · Cited by 5
Self-citation
Parkinson’s Disease and Gastrointestinal Non Motor Symptoms: Diagnostic and Therapeutic Options – A Practise Guide
Klingelhoefer, L., & Reichmann, H. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-150574 · Cited by 5
Consensus statements on diagnosis and management of chronic idiopathic constipation in adults in Hong Kong
Wu, J. C., Chan, A. O. O., Cheung, T., KWAN, A. C., Leung, V. K., Sze, W. C., & Ta, V. P. (2019) · Hong Kong Medical Journal · doi:10.12809/hkmj187692 · Cited by 5
Gastrointestinal drugs
Blandizzi, C., & Scarpignato, C. (2014) · Side effects of drugs annual · doi:10.1016/b978-0-444-62635-6.00036-x · Cited by 5
Linaclotide
Cada, D. J., Levien, T. L., & Baker, D. E. (2013) · Hospital Pharmacy · doi:10.1310/hpj4802-143 · Cited by 5
Comparison of the Efficacy and Safety of Different Doses of Linaclotide for Patients with Chronic Constipation: A Meta-Analysis and Bayesian Analysis
Yang, J., & Lei, Y.-C. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/9923879 · Cited by 4
“Linaclotide at doses of 145 μg and 290 μg has demonstrated an adequate level of safety and efficacy in two large RCTs conducted on CC patients [18].”
Background
Management of the child with refractory constipation
van der Zande, J. M. J., & Lu, P. L. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17847 · Cited by 5
Efficacy and safety of linaclotide in treatment‐resistant chronic constipation: A multicenter, open‐label study
Yoshihara, T., Kessoku, T., Takatsu, T., Misawa, N., Ashikari, K., Fuyuki, A., Ohkubo, H., Higurashi, T., Iwaki, M., Kurihashi, T., et al. (2024) · Neurogastroenterology & Motility · doi:10.1111/nmo.14938 · Cited by 4
Defining Optimal Care for Functional Gut Disorders - Multi-Disciplinary Versus Standard Care: A Randomized Controlled Trial Protocol
Basnayake, C., Kamm, M. A., Salzberg, M. R., Khera, A. J., Liew, D., Burrell, K., Wilson-O'Brien, A. L., Stanley, A., Talley, N. J., & Thompson, A. J. V. (2019) · Contemporary Clinical Trials · doi:10.1016/j.cct.2019.105828 · Cited by 4
Guanylin, Uroguanylin and Guanylate Cyclase-C Are Expressed in the Gastrointestinal Tract of Horses
Cappelli, K., Gialletti, R., Tesei, B., Bassotti, G., Fettucciari, K., Capomaccio, S., Bonfili, L., Cuccioloni, M., Eleuteri, A. M., Spaterna, A., et al. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01237 · Cited by 4
The Effect of Acupressure on Constipation: A Systematical Review
Şahan, S., & Yıldız, A. (2020) · International Journal of Clinical & Medical Informatics · doi:10.46619/ijcmi.2020.1027 · Cited by 4
Treatment and Management of Gastrointestinal Disorders
Montgomery, G., Patel, A., & Pfeil, S. A. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2024.03.010 · Cited by 4
Recent Advances in the Management of Difficult Constipation
Lacy, B. E., Levenick, J. M., & Crowell, M. D. (2012) · Current Gastroenterology Reports · doi:10.1007/s11894-012-0269-1 · Cited by 5
Benefit–Risk Assessment of Plecanatide in the Treatment of Chronic Idiopathic Constipation
Miner, P. B. (2019) · Drug Safety · doi:10.1007/s40264-018-0781-9 · Cited by 4
The endogenous ligand for guanylate cyclase-C activation reliefs intestinal inflammation in the DSS colitis model
Lan, D., Wen, Y., Dong, X., Yang, Q., Liu, Y., Wang, K., Li, H., & Miao, Y. (2020) · Acta Biochimica Polonica · doi:10.18388/abp.2020_2881 · Cited by 4
“Recent studies reported that GC-C agonists plecanatide and linaclotide can be used in the treatment of chronic idiopathic constipation (Lembo et al., 2011; Islam et al., 2018).”
Background
Psychometric validation of patient-reported outcome measures assessing chronic constipation
Williams, V. S. L., Fehnel, S. E., Carson, R. T., MacDougall, J., Baird, M. J., Tourkodimitris, S., Kurtz, C. B., Johnston, J. J., & Nelson, L. M. (2014) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s64713 · Cited by 4
Self-citation
Management of Constipation in Patients With Parkinson Disease
Noll, L. M. (2013) · Journal of Hospice and Palliative Nursing · doi:10.1097/njh.0b013e3182a32a31 · Cited by 4
Efficacy and Safety of Linaclotide in Elderly Patients
Ishigo, T., Shimotsubo, T., Takada, R., Nakano, K., Fujii, S., Kitagawa, M., Kimyo, T., Nakata, H., & Fukudo, M. (2021) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.20-00176 · Cited by 4
Pharmacological, Pharmacokinetic, and Pharmacogenomic Aspects of Disorders of Gut–Brain Interaction
Camilleri, M., Sarnelli, G., Andresen, V., Meerveld, B. G., Howden, C. W., Izzo, A. A., & Jones, K. L. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.02.010 · Cited by 3
On-Resin Acetamidomethyl (Acm) Removal and Disulfide Formation in Cysteinyl Peptides Using N-Chlorosuccinimide (NCS) in the Presence of Other Cys-Protecting Groups
Chakraborty, A., Alberício, F., & de la Torre, B. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062523 · Cited by 3
“For example, Linaclotide, a 14-mer peptide with three disulfide bridges, is used for the treatment of irritable bowel syndrome [10,11].”
Ghrelin Agonists as Emerging Prokinetic Agents
Tack, J. F., & Corsetti, M. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.08.032 · Cited by 3
Reoperation in an adult female with "right-sided" Hirschsprung's disease complicated by refractory hypertension and cough
Wei, Z., Huang, L., & Xu, A. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i41.9235 · Cited by 3
Treatment failure in children diagnosed with constipation in a paediatric emergency department in relation to Rome III criteria
Eltorki, M., Bhattacharjee, A., Khan, M., Martin, E., Shyleyko, R., & Freedman, S. B. (2018) · Paediatrics & Child Health · doi:10.1093/pch/pxy121 · Cited by 3
“, antidepressants, prosecretory agents) are reserved for severe cases (19,20).”
Background
Obstipation – Pathophysiologie, Diagnostik, Behandlung
Müller-Lissner, S. A. (2019) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-0670-5209 · Cited by 4
“[13] Lembo AJ, Schneier HA, Shiff SJ et al.”
Background
Evaluation of Constipation and Treatment of Abdominal Component
Garrett, K. A., & Ogilvie, J. W. (2021) · Springer eBooks · doi:10.1007/978-3-030-66049-9_58 · Cited by 3
Exploratory, multicenter, open-label study to evaluate the effects of linaclotide in patients with chronic constipation with an insufficient response to magnesium oxide: A study protocol
Yoshihara, T., Kessoku, T., Takatsu, T., Misawa, N., Ashikari, K., Fuyuki, A., Ohkubo, H., Higurashi, T., Iwaki, M., Kurihashi, T., et al. (2022) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2022.101019 · Cited by 3
“In a randomized controlled trial where low-dose linaclotide was administered orally for chronic constipation, the mean age of the subjects was less [7, 12].”
Background
Recent advances in the treatment of gastrointestinal motility disorders in children
Niță, A. F., Chanpong, A., Nikaki, K., Rybak, A., Thapar, N., & Borrelli, O. (2023) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2023.2295495 · Cited by 4
“Another noninvasive therapeutic option is neuromodulation [150] through the application of electrical stimulation on nerve fibers to modulate neuronal activity.”
Background
The multidimensional clinical profile for disorders of gut-brain interaction
Iyengar, P., & Chang, L. (2024) · NeuroGastroLATAM Reviews · doi:10.24875/ngl.23000008 · Cited by 3
Pharmacologic Treatment of Chronic Constipation
Wang, H., & Lee, J. W. (2024) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2024.045 · Cited by 3
Examining linaclotide for the treatment of chronic idiopathic constipation
Taclob, J. A., Kalas, M. A., & McCallum, R. W. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2386160 · Cited by 3
“In a 12-week trial by Lembo et al., patients receiving linaclotide had comparable types and rates of adverse events [74].”
Rectal prolapse (62.2, 62.3), adults
Shelygin, Y. A., Иванович, А. С., Alyoshin, D. V., Biryukov, O. M., Грошилин, В. С., Кашников, В. Н., Kostarev, I. V., Kostenko, N. V., Moskalev, A., Mudrov, A. A., et al. (2024) · Koloproktologia · doi:10.33878/2073-7556-2024-23-3-10-22 · Cited by 3
A real-world study of persistence and adherence to prescription medications in patients with chronic idiopathic constipation in the United States
Cash, B. D., Lü, M., Lembo, A. J., Feuerstadt, P., Nguyen, L. A. B., Terasawa, E., Ayyagari, R., Du, S., Pi, S., Westermeyer, B., et al. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.30.10.1136 · Cited by 3
Self-citation
Linaclotide in the treatment of patients with irritable bowel syndrome and constipation - analysis of an opportunity.
Carballo, F. (2013) · Revista Espanola de Enfermedades Digestivas · doi:10.4321/s1130-01082013000600006 · Cited by 1
“En fase III se realizaron dos EC multicéntricos aleatorizados, controlados con placebo y doble ciego en pacientes con estreñimiento publicados conjuntamente (39).”
Background
Guanylate cyclase C signaling: an intestinal secretory pathway where bugs, genes and new drugs intersect
Camilleri, M. (2012) · Genome Medicine · doi:10.1186/gm349 · Cited by 3
“Since analogs of guanylin and uroguanylin (linaclotide and plecanatide [7,8]) already exist, clinical translation of the science to develop secretagogue drugs for relief of constipation and associated symptoms (bloating and abdominal pain) had preceded the intriguing molecular genetic discovery of Fiskerstrand et al.”
Background
The Influence of Polypharmacy on Nutrition
Piccolo, K., & Boullata, J. I. (2015) · Springer eBooks · doi:10.1007/978-3-319-22431-2_6 · Cited by 3
A Case-Based Approach to Constipation in Primary Care
Snell, D. B., Faruqui, S., & Bosworth, B. P. (2020) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.08.015 · Cited by 3
Pharmacological treatment for children with constipation: present and future
van der Zande, J. M. J., Koppen, I. J. N., Lorenzo, C. D., Lu, P. L., & Benninga, M. A. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2471524 · Cited by 4
Guanylin ligand protects the intestinal immune barrier by activating the guanylate cyclase-C signaling pathway
Xing, C., Zhang, T., Liu, X., Li, C., Yang, G., Zhang, H., Wang, R. Y., Wang, K., Miao, Y., & Lan, D. (2021) · Acta Histochemica · doi:10.1016/j.acthis.2021.151811 · Cited by 2
Seoul Consensus on Clinical Practice Guidelines for Functional Constipation
Song, K. H., Cho, Y. S., Shin, J. E., Jung, H., Park, S., Kang, S. J., Kim, J., Lee, Y. J., Lim, H. C., Park, H. S., et al. (2025) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2024.156 · Cited by 2
Irritable Bowel Syndrome in Inflammatory Bowel Disease: An Evidence-Based Practical Review
Butt, M. F., Reghefaoui, M. H., Benedict, A. S., Reghefaoui, M., Al-Jabir, H. M., Shaikh, A., Vojtekova, K., Moran, G. W., Corsetti, M., & Aziz, Q. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm15010116 · Cited by 3
Non-neoplastic disorders in an aging gut: concise review
Dawra, S., Behl, P., Srivastava, S., Manrai, M., Chandra, A., Kumar, A., Kumar, A., & Tevatia, M. S. (2023) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-023-00189-1 · Cited by 2
“Guanyl cyclase C receptor-Linaclotide has shown neuromodularity effects in functional constipation [62].”
Background
Usefulness of Elobixibat in Patients With Chronic Constipation After Cholecystectomy
Sakai, Y., Tsuyuguchi, T., Kumagai, J., Ohyama, H., Kaiho, T., Ohtsuka, M., & Kato, N. (2024) · Cureus · doi:10.7759/cureus.67132 · Cited by 2
“In pharmacotherapy, drugs with various mechanisms of action are available, and their usefulness has been reported [12-16].”
Background
Efficacy of elobixibat for elderly patients with chronic constipation in a clinic
Sakai, Y., Tsuyuguchi, T., Kumagai, J., Ohyama, H., Kaiho, T., Ohtsuka, M., & Kato, N. (2025) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v16.i2.105801 · Cited by 2
Randomised clinical trial: effects of MD ‐7246 on irritable bowel syndrome with diarrhoea
Lembo, A. J., Kuo, B., Boinpally, R., Li, E., Mallick, M., Bochenek, W. J., & Bartolini, W. P. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17274 · Cited by 2
Self-citation
Irritable Bowel Syndrome: Pathophysiology and Goals of Therapy
Schoenfeld, P., Lembo, A. J., Cash, B. D., & Pimentel, M. (2015) · Cited by 2
Self-citation
Constipación crónica. Conceptos actuales desde la fisiopatología hasta el tratamiento
García‐Zermeño, K. R. (2021) · Acta gastroenteorológica latinoamericana/Acta gastroenterológica latinoamericana · doi:10.52787/zrrj9030 · Cited by 4
Rationale and design of a multicentre, 12-week, randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated trial to investigate the efficacy and safety of elobixibat for chronic constipation
Tanaka, K., Kessoku, T., Yamamoto, A., Takahashi, K., Kasai, Y., Ozaki, A., Iwaki, M., Kobayashi, T., Yoshihara, T., Misawa, N., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-060704 · Cited by 2
“Efficacy after two weeks of administration cannot be said to indicate improvement in the chronic aspect of chronic constipation; thus, to show the effectiveness of the study drug in chronic cases, we set our endpoint to the degree of change in CSBMs at Week 12 of treatment [16].”
Background
Irritable Bowel Syndrome
Kim, N. (2022) · Springer eBooks · doi:10.1007/978-981-19-0120-1_16 · Cited by 2
Cross-linked survey analysis is an approach for separating cause and effect in survey research
Redelmeier, D. A., Thiruchelvam, D., & Lustig, A. J. (2014) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2014.09.008 · Cited by 2
Current treatment paradigm and landscape for the management of chronic idiopathic constipation in adults: Focus on plecanatide
de Andino, N. M. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000090 · Cited by 3
Irritable Bowel Syndrome
Videlock, E. J., & Chang, L. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch75 · Cited by 2
Intramolecular Hydrogen Bonding Enables a Zwitterionic Mechanism for Macrocyclic Peptide Formation: Computational Mechanistic Studies of CyClick Chemistry
Shao, H., Adebomi, V., Bruce, A., Raj, M., & Houk, K. N. (2023) · Angewandte Chemie · doi:10.1002/ange.202307210 · Cited by 1
Fecal Microbiota Transplantation in the Treatment of Severe Constipation in Children: Is It the Future?
Stefano, M. D. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002985 · Cited by 1
Von Inkontinenz bis Obstipation – medikamentöse Aspekte in der Urogynäkologie
von Schell, J., Molnar, P., & Hübner, M. (2025) · Die Gynäkologie · doi:10.1007/s00129-024-05328-5 · Cited by 1
Pharmacotherapy for Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome Beyond Conventional Laxatives: A Narrative Review
Sahu, S., Nath, P., Mallick, B., Praharaj, D., Giri, S., Panigrahi, S., Anand, A., & Sahu, M. (2025) · Cureus · doi:10.7759/cureus.97523 · Cited by 2
“Adverse events were similar between groups except for diarrhea, which caused discontinuation in 4.2% of linaclotide-treated patients [26].”
Influential
Diagnóstico y tratamiento de la constipación crónica
Defilippi, G. C., Salvador, U. V., & Larach, K. (2013) · Revista Médica Clínica Las Condes · doi:10.1016/s0716-8640(13)70159-7 · Cited by 1
“Al menos dos ERC publicados en el 2011 que determinaron su utilidad por un período de 12 semanas, en dos diferentes dosis (145 o 290 mcg/día) (21), demostraron que este fármaco disminuye significativamente las molestias intestinales y abdominales en paciente con constipación crónica.”

Authors: Lembo, A. J., Schneier, H. A., Shiff, S. J., Kurtz, C. B., MacDougall, J. E., Jia, X. D., Shao, J. Z., Lavins, B. J., Currie, M. G., Fitch, D. A., Jeglinski, B. I., Eng, P., Fox, S. M., & Johnston, J. M.
Affiliations: Beth Israel Deaconess Medical Center (US)
Forest Laboratories (United States) (US)
Ironwood Pharmaceuticals (United States) (US)
ORCID: Lembo, Anthony J.
Currie, Mark G.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2011-08-11
Volume: 365
Issue: 6
Pages: 527-536
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1010863
OpenAlex: W2129385409
Cited by: 373
References: 18
Citations by year: 2026: 16 · 2025: 12 · 2024: 28 · 2023: 22 · 2022: 19 · 2021: 23 · 2020: 23 · 2019: 20 · 2018: 31 · 2017: 24 · 2016: 32 · 2015: 26 · 2014: 26 · 2013: 40 · 2012: 25
FWCI: 31.44
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Ironwood Pharmaceuticals, Incorporated
Topics: Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Health Sciences › Medicine › Urology › Pelvic floor disorders treatments
Health Sciences › Medicine › Surgery › Congenital gastrointestinal and neural anomalies
Keywords: linaclotide, chronic constipation, spontaneous bowel movements, diarrhea, drug safety, treatment efficacy
MeSH terms: Adolescent, Adult, Aged, Aged, 80 and over, Chronic Disease, Constipation, Defecation, Diarrhea, Double-Blind Method, Female, Guanylate Cyclase, Humans, Male, Middle Aged, Peptides, Quality of Life, Withholding Treatment, Receptors, Guanylate Cyclase-Coupled, Laxatives, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Two Randomized Trials of Linaclotide for Chronic Constipation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks